Member Info for countingcards

I believe Mr Lang has till March 31st to decide about the loan note convertion at 1.4p so that may be weighing down on current price, and Q2 is April 1st to June 30th. Based on these two factors which are just a couple within the larger picture. When it comes to saving lives you don't want to rush the process just to keep a few closet traders happy.

Https://www.londonstockexchange.com/news-article/CIZ/progress-on-launch-of-biomarker-test-in-usa/17471368

I believe the loan notes were to be converted at a rate of £50k monthly and that so far has not happened but Fraser has until March 31st 2026 to convert otherwise it gets written into debt without any interest payable or dilution to the company.

If I am reading this correct, Fraser Lang has until to 31st March 2026 to decide whether to convert the £250000 CLN announced on 5th November 2025. This will be at 1.4p which is where we are roughly now, and that will convert into 17,857,142 new shares. If, however, he decides not to convert, there are no associated fees or interest payments due to him from CIZ. He may also decide not to have the money returned in which case, from 5th November 2025 RNS “Prior to 31 March 2026 the Company does not intend to incur any debt (other than in the ordinary course of business) or make any adjustments to its share capital while the Additional Notes are outstanding.” It will become a debt but there will be no further dilution.

The note which was announced in May 2025 however was for £150000 and again could be converted into new ordinary shares at 1.4p any time up to 24 months from announcement. That would be 10,714,285 shares potentially with I am sure the same stipulations as the later loan notes 5th November 2025.

The Company has also issued warrants to Frazer Lang over 12,500,000 Ordinary Shares in the Company at an exercise price of 2p, to be exercised within two years of the date of issue.

So, in total that is around a potential 41,071,428 shares that could be issued taking the Fraser Lang to 19.48% of the issued share capital two years from the dates of announcement.

I am wondering if this is why we have been hovering around here, waiting basically on any dilution from Lang and we have until the 31st of March 2026 potentially to know. New tax year a week after that and hopefully we swing into action a little wiser.

If our lives similarly were determined by just one day, would it be fair to determine a whole life by that day?

Courtesy of Bubbles223 on IMM. Just found it an interesting read and most of it related to IMM which I am not invested in.

When a biotech is getting close to signing a partnership, it almost never says so directly — but it always leaves a trail of signals. Investors who follow deal‑making watch these patterns closely because they tend to repeat across companies and across years.

Here’s a deeper look at how companies signal a deal is close, with each signal broken down into what it really means behind the scenes.

🔍 The Subtle (but Reliable) Signals a Deal Is Near

1. Senior leadership suddenly becomes very visible

CEO and CSO attending partnering events together

Multiple executives presenting instead of just one

Frequent interviews or investor updates

When a deal is early, business development teams handle it.

When a deal is close, executives must be present because final terms require top‑level approval.

2. The company attends high‑level partnering conferences

JP Morgan Healthcare Conference

BIO International Convention

Biotech Showcase in San Francisco

These events are where final negotiations often happen.

Companies don’t send their full leadership team unless they expect meaningful progress.

3. Language in press releases becomes more specific

Look for shifts like:

“We are in discussions” → “advanced discussions with multiple parties”

“Exploring options” → “detailed due diligence underway”

“Engagement ongoing” → “multiple confidentiality agreements signed”

Public companies choose their words carefully.

When the language tightens, it’s intentional.

4. Silence — the good kind

Fewer scientific updates

No new exploratory programs announced

Reduced commentary on timelines

When a deal is close, companies often go quiet because:

they’re under NDA

they don’t want to disrupt negotiations

they’re preparing coordinated announcements with the partner

Silence is often louder than words.

5. The company begins referencing “value inflection” events

“Transformational opportunity”

“Strategic partnership discussions”

“Multiple interested parties”

This is coded language for:

We’re negotiating, and we want the market to know something big is coming.

🧠 The strongest signal of all

When a company says it is:

meeting multiple top‑10 pharma companies,

attending JP Morgan with its full leadership team, and

has multiple confidentiality agreements signed,

that confidentiality agreements signed,

This is a sign that a deal is in the late stages.

You mean retail who may have gone for the rights might now decide instead its better to buy shares in the open market? Because the shares are a fraction cheaper than 25p?

Indiana Farm Bureau Insurance who just expanded the LeakBot programme in November 25, contracting a rollout of a further 10,000 devices commencing before the end of the year, have committed to taking 3,031,200 shares in the placing for £0.76m which will give them 2.05% of the enlarged shares. So either they hold as they understand the partnership value or they sell at a loss. Not hard to work out what they will do.

Made an absolute mistake when these were 6p when I listened to an interview from Craig and dismissed that this would ever really take off. Then a year ago looked at it again and ever since have been adding slowly. Thankfully corrected a personal stupid error of judgement and hats off and apologies for dismissing craig initially. Yet another really great piece of news on progress today.

Given that the original RTO price was 10p, and that since then with dilution etc, I make the equivalent to be 5.65p. So that would be the first port of call . Once there, its possible a lot of shuffling around will occur with stale bulls leaving, others trimming holdings, traders moving on after getting to 5.65p, and new stable investors joining and the price gradually begins to mirror the success of the company going forward. No real prediction as to where price should be within a year, but certainly where it is now shows that there is a lack of interest which is not a big deal, because sensible money will follow sensible news and behave in a orderly manner, while stupid money will follow emotional behaviour and act erratically.

The aim is to see this company save lives, and personally its been just over 5.5 years for me and building over 12 times more than at RTO, given the progress. If pushed ideally I would like it to be around 10p as the base. The current price is artificial but one which the market dictates away from the newsflow present and future but because emotional erratic traders who cannot and will not see the bigger picture but want to actually trade it! LOL. That is one of the major reasons for the current levels.

As I see it you would not be announcing the UK news today unless the US part was a very close done deal. I think the nerves must be getting to the traders amongst us who must now realise to sell would be fine if you make a profit but is that profit v close confirmation worth it. I know it can be argued the price has channelled too often in a range, but this one does seem different. You do get the feel that this news today was not the end of it for now.

No interest in the traders, but more and more of the stock over the years has gone into firmer hands that is for sure. You can focus on the day to day shareprice or the underlying strength the company is building. The confidence to announce it has entered into a Letter of Intent with a leading medical diagnostic services provider acting in partnership with the NHS, shows that the US side of the business is about to be unveiled soon.

Fraser Lang and family, their continuous support that they do not want any interest on the CLN to hinder the company and will not exercise warramts for 2 years. Cannot see any negatives in the news announced today but ongoing progression.

This was in the interims today:

“Net fair value loss on financial asset: £Nil (H1 2024: £1,081,000) (related to a current asset investment in Conduit Pharmaceuticals Inc ("Conduit"), a NASDAQ listed company, that was sold in H1 2025 for a loss on sale of investment £26,000 (H1 2024: £Nil).”

Was this not worth £3.25m to Cizzle in AZD1656 at one stage back around December 2022? We then issued shares to Conduit in return for a share in their NASDAQ listing, by giving up that 5% holding to them, and by taking 5% of the share issue on IPO in Conduit. That in turn has gone from £3.25m to a £26k loss.

Am I missing something here? I might have missed a lot more of the detail here. We issued a ton of shares to Conduit who then duly sold them asap and we were diluted as shareholders. This certainly does not look like a good deal in the end.

Https://www.londonstockexchange.com/news-article/CIZ/interim-results/17254566

Well what it has done has caused the highest share volume since 3rd Feb 2022 (which was still higher), even with one of the transactions today recorded as a cancellation. So technically its a little artificial.

TT

I was going to ask if you had sent in multiple emails, but I think you cleared that up by saying they were infrequent. You may also have been caught in some sort of crossfire, in that multiple emails sent, does sound the work of a nutter, and we have one on here who gets frequently banned. Otherwise BB's reaction would be out of character for just one email!

Also some who can remember from the early days around RTO, it took around 550 days from suspension to actually coming back as CIZ, with BOU in between and not a single leak as to what was going to come. Patient then, although sometimes tested, to what I would term for me, a comfortable patience now. The area they are working within is pretty sensitive so one can understand why news is few and far between, and can test you.

Personally I do think they care about shareholders if approached in the right way.

The email you received thanks for sharing. However from its wording it would read slightly unprofessional or that you have reworded it. Can we trust what the company is saying? Do you think its BS they will be receiving payments in advance, and they would be that stupid to announce it to the investment world risking all if that was not true? I make that around £117k per month (averaging) received in guaranteed payments till December 2026.

Your one line you kindly shared from the email you received was "We were just helping with some experiments and not really a part of the clinical undertaking."

This then make sense in context to this from the RNS, which clearly states the actual role of iGenomeDX.

"At the time, BIO's strategy was to then complete further contracts with other laboratory partners to roll out the test more widely once iGenomeDX had completed their work. However, following the progress made by iGenomeDX as the pathfinder clinical laboratory, BIO's strategy has developed to more appropriately reflect the large market opportunity they are seeing for the Company's CIZ1B biomarker test in North America."

You can either let your trade run on, or you can cash in on your gamble, but you should not be aligning future progression to a near term bet, or stressing yourself. For investors especially LTH its welcomed news. Thanks for sharing the email.

Found this post on Linkedin. Sorry to hear this , and he did a lot in the initial stages.

Antos J. Glogowski was a pioneer of renewable energy in the UK and a very successful individual. For those who knew him, he was a mentor and friend, guiding many through their careers in the industry. It was heartbreaking to hear the news of his demise a couple of days ago. I remember meeting him for the first time in Charing Cross station with his fluffy hair and a big smile on his face. He will be missed by many people. Rest in peace, Antos.

TT you are welcome. Your ego will protect you from the truth.

"Then they go onto mention Private Equity will at some stage be needed -that could have all sorts of ramifications."

CEOCFO: Are you seeking funding, investment or additional partnerships?

Mr. Behnke: Yes, we are currently accepting investments and actively building relationships with strategic partners. To date, our funding has come from private individuals and angel investors who are aligned with our mission and see the strong potential in our approach to early cancer detection. We have not pursued venture capital or private equity at this point as we have been focused on building a strong clinical and business foundation.

NOTE: "We have not pursued venture capital or private equity at this point"

If all is going to plan then 1.5, 1.6, 1.7, 1.8, etc makes no difference. If you are trading it then I can understand why it has relevance. Given that 5.65p would be similar to the 10p IPO (something I brought up before, due to placings since) then multiples of that is what holders are after, given the potential. Again to traders, this would be 'fear of heights' as they are not interested in the business case, but rather the 0.1p increments before someone else grabs it.

https://en.wikipedia.org/wiki/Stanford_marshmallow_experiment